Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
CA 2092827 A1 · Owner: Slaoui, Moncef · Inventors: Van Wijnendale, Frans; Kummert, Suzy; Francotte, Myriam
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides novel substantially uncleavable forms of, gp160 and vaccine formulations containing gp160 or a derivative thereof, adjuvanted with 3-D Mpl. The compositions are useful for the immunotherapeutic and immunoprophylactic treatment of HIV infections.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 21, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 21, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 21, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.